Revista de Neurología,
Journal Year:
2024,
Volume and Issue:
79(02), P. 51 - 51
Published: Jan. 1, 2024
The
XVI
Post-ECTRIMS
meeting
was
held
in
Seville
on
20
and
21
October
2023,
where
expert
neurologists
multiple
sclerosis
(MS)
summarised
the
main
new
developments
presented
at
ECTRIMS
2023
congress,
which
took
place
Milan
from
11
to
13
October.
aim
of
this
article
is
summarise
content
Meeting,
an
two
parts.
This
second
part
covers
health
women
elderly
MS
patients,
trends
treatment
cognitive
impairment,
focusing
particularly
meditation,
neuroeducation
rehabilitation,
introduces
concept
fatigability,
has
been
used
a
limited
extent
MS.
key
role
digitalization
artificial
intelligence
theoretically
near
future
subject
debate,
along
with
potential
these
technologies
can
offer.
most
recent
research
various
algorithms
their
efficacy
safety
management
disease
reviewed.
Finally,
relevant
data
for
cladribine
evobrutinib
are
presented,
as
well
therapeutic
strategies
currently
being
investigated.
Neurology,
Journal Year:
2025,
Volume and Issue:
104(3)
Published: Jan. 16, 2025
Hepatitis
B
vaccination
(HBV)
requires
6
months
to
complete
and
is
recommended
for
patients
with
multiple
sclerosis
(PWMS),
particularly
those
who
are
candidates
anti-CD20
therapy.
However,
limited
data
exist
on
HBV
immunogenicity
in
PWMS
receiving
disease-modifying
therapies
(DMTs)
the
impact
of
starting
therapy
during
immunization.
We
aimed
evaluate
vaccination,
focusing
number
doses
received
before
initiation.
conducted
a
retrospective
analysis
prospective
cohort
adult
at
single
center
Spain,
from
April
2015
May
2023.
Eligible
participants
completed
4-dose
course
underwent
postvaccination
serologic
testing.
assess
seroprotection
rates
(SRs),
defined
as
percentage
achieving
anti-hepatitis
surface
antibody
titers
≥10
IU/L,
switched
based
type
DMT
start.
A
multivariate
generalized
linear
model
(GLM)
was
used
identify
factors
associated
higher
seroconversion.
total
289
(median
[interquartile
range
(IQR)]
age,
47.7
[42.8-54.4]
years;
65.7%
female;
median
[IQR]
disease
duration,
14.8
[6.7-21.2]
years)
were
included.
SRs
progressively
declined
fewer
initiation,
92.8%
(95%
CI
87.1-96.5)
4
24.0%
9.4-45.1)
1
dose.
Patients
transitioning
sphingosine
1-phosphate
(S1P)
modulators
showed
lowest
SR
25.0%
7.3-52.4).
The
GLM
confirmed
these
findings,
3
(SR
ratio
3.23
[95%
1.68-6.23];
p
=
0.0005)
or
3.76
1.96-7.24];
<
0.0001)
significantly
SRs,
while
S1P
onset
lower
0.42
0.23-0.78];
0.0058).
Female
sex
1.15
1.01-1.32];
0.0389)
younger
age
0.90
0.83-0.97];
0.0036)
also
SRs.
Initiating
negatively
affects
direct
correlation
Early
planning
execution
required
vaccinations
crucial
managing
PWMS.
This
study
provides
Class
III
evidence
that
initiation
less
effective
establishing
hepatitis
than
whom
Multiple Sclerosis Journal,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 12, 2025
Background:
Vaccination
in
patients
with
multiple
sclerosis
(PwMS)
presents
unique
challenges.
Disease-modifying
therapies
(DMTs)
can
increase
infectious
risks,
though
these
are
largely
preventable
through
immunizations.
However,
DMTs
also
reduce
vaccine
efficacy.
Aims:
This
study
aimed
to
identify
challenges
achieving
effective
immunization
for
PwMS
and
explore
strategies
optimize
vaccination
practices.
Methods:
Recent
guidelines
studies
on
were
reviewed
pinpoint
challenges,
unmet
needs,
opportunities
improvement.
Results:
Early
before
DMT
initiation
is
vital
optimal
responses,
coordinating
vaccinations
DMTs’
Strategies
enhance
efficacy,
such
as
bridging
or
more
immunogenic
formulations,
may
benefit
highly
active
requiring
immediate
initiation.
Although
live-attenuated
vaccines
pose
those
immunosuppressive
therapies,
emerging
evidence
suggests
safe
administration
select
cases.
Overcoming
hesitancy
demands
targeted
education,
personalized
counseling,
improved
access
services,
especially
low-
middle-income
countries.
Inclusivity
crucial,
particularly
groups,
pediatric,
pregnant,
elderly
PwMS.
Conclusion:
A
multifaceted
approach
essential
addressing
Collaborative
efforts
involving
stakeholders
crucial
overcoming
obstacles
generating
robust
evidence.
We
propose
an
integrated
strategy
ensure
while
maintaining
timely
administration.
JAMA Network Open,
Journal Year:
2024,
Volume and Issue:
7(4), P. e246345 - e246345
Published: April 12, 2024
Vaccination
in
patients
with
highly
active
multiple
sclerosis
(MS)
requiring
prompt
treatment
initiation
may
result
impaired
vaccine
responses
and/or
delay.
Therapeutic Advances in Infectious Disease,
Journal Year:
2025,
Volume and Issue:
12
Published: Jan. 1, 2025
This
narrative
review
explores
the
risks
related
to
infection
in
immunocompromised
travelers
due
conditions
other
than
transplantation,
and
evaluates
evidence
behind
current
prophylactic
strategies,
including
immunizations,
antimicrobials,
non-pharmacological
interventions,
prevent
various
how
applies
this
special
patient
population,
from
perspective
of
a
US-based
traveler.
Journal of Integrative Neuroscience,
Journal Year:
2025,
Volume and Issue:
24(1)
Published: Jan. 21, 2025
The
complicated
neurological
syndrome
known
as
multiple
sclerosis
(MS)
is
typified
by
demyelination,
inflammation,
and
neurodegeneration
in
the
central
nervous
system
(CNS).
Managing
this
crippling
illness
requires
an
understanding
of
complex
interactions
between
neurophysiological
systems,
diagnostic
techniques,
therapeutic
methods.
A
series
processes,
including
immunological
dysregulation,
neurodegeneration,
are
involved
pathogenesis
MS.
Gene
predisposition,
autoreactive
T
cells,
B
cytokines
essential
participants
development
disease.
Demyelination
interferes
with
ability
CNS
to
transmit
signals,
which
can
cause
a
variety
symptoms,
impaired
motor
function,
sensory
deficiencies,
cognitive
decline.
Developing
tailored
therapeutics
underlying
processes
guiding
course
Neuroimaging,
laboratory
testing,
clinical
examination
all
necessary
for
accurate
MS
diagnosis.
Evoked
potentials
cerebrospinal
fluid
studies
assist
verifying
diagnosis,
but
magnetic
resonance
imaging
(MRI)
identifying
distinctive
lesions
CNS.
Novel
biomarkers
have
potential
increase
precision
forecast
prognosis.
goals
treatment
options
control
lower
disease
activity,
enhance
quality
life.
To
stop
relapses
reduce
disease,
disease-modifying
treatments
(DMTs)
target
several
components
immune
response.
DMTs
that
now
on
market
include
interferons,
glatiramer
acetate,
monoclonal
antibodies,
oral
immunomodulators;
each
has
unique
mode
action
safety
profile.
Symptomatic
improve
patients'
general
well-being
addressing
specific
pain,
sphincter
disorders,
fatigue,
spasticity.
targets,
neuroprotective
tactics,
personalized
medicine
techniques
will
be
main
focus
research
future.
Improving
long-term
outcomes
patients
optimizing
may
possible
utilizing
immunology,
genetics,
neuroimaging
developments.
This
study
concludes
highlighting
complexity
MS,
its
changing
landscape,
problems,
foundations.
thorough
grasp
these
elements
improving
our
capacity
identify,
manage,
eventually
overcome
intricate
condition.
Therapeutic Advances in Neurological Disorders,
Journal Year:
2025,
Volume and Issue:
18
Published: Jan. 1, 2025
Complete
vaccination
coverage
is
recommended
by
multiple
sclerosis
(MS)
societies
for
patients
with
(pwMS)
to
mitigate
infection
risks
associated
disease-modifying
therapies
(DMTs).
To
analyze
and
its
determinants
in
pwMS
compared
healthy
controls,
considering
hesitancy,
MS-specific
beliefs,
trust
information
sources,
the
role
of
general
practitioners
(GPs).
This
cross-sectional
multicenter
observational
study
was
conducted
six
German
MS
centers.
The
primary
endpoint
a
index
(VI)
comprising
eight
standard
vaccinations
(range
0-1,
higher
VI
indicating
better
coverage).
Secondary
endpoints
included
validated
measures
sources.
Data
were
collected
through
questionnaires,
card
analysis,
survey
GPs
who
vaccinate
pwMS.
tended
be
lower
(n
=
397)
controls
300;
0.58
±
0.30
vs
0.62
0.31,
p
0.057).
In
receiving
highly
effective
DMTs,
did
not
differ
significantly
from
those
on
no/platform
DMTs.
Vaccination
hesitancy
comparably
low,
no
differences
between
controls.
sources
explained
only
10%-16%
variance
VI.
Among
109
GPs,
82%
cited
reluctance
due
concerns
about
MS-related
side
effects
or
interactions
Despite
clear
recommendations
full
all
pwMS,
remains
worryingly
low.
Approximately
half
lack
coverage,
even
fact,
than
other
intrinsic
factors
do
sufficiently
explain
low
rates.
Inconsistent
uncertainties
vaccine
safety
DMT
likely
contribute.
